Freedom’s Just Another Word for . . . Restriction?
By Alice Dreger,
Bioethics Forum
| 04. 27. 2011
What tools does a university administration have at its disposal to shut up critics on its own faculty? The University of Minnesota wants to know.
The university's administration is exploring this question because its own Carl Elliott won't shut up about the Markingson case. Elliott, a professor in the Center for Bioethics, just keeps talking about what went wrong at his medical school in a 2003 industry-sponsored drug trial in which research subject Dan Markingson killed himself. Since publication of a muckraking article on the subject in Mother Jones, Elliott has criticized the FDA's response to the case and led a group of faculty in asking the University Trustees to look into the case.
Like many others who continue to follow this story, Elliott is drawn to this case by issues of justice both local and global. Locally, he seeks accountability for what happened to Dan Markingson and to his mother, who tried repeatedly before Dan's gruesome suicide to convince involved clinicians that study participation went against Dan's best interests.
But Elliott also sees in this story the impetus for...
Related Articles
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Sophie Alexander and Ike Swetlitz, Bloomberg | 06.25.2025
A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to one of the most controversial technologies in medicine.
Bootstrap Bio...
By Siddhi Mahatole and Mariam E. Sunny, Reuters | 06.13.2025
Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals' (REGN.O), opens new tab offer for the DNA-testing company in a bankruptcy auction.
Last month, Regeneron agreed to...